02012nas a2200385   4500000000100000008004100001260000900042653002600051653002300077653002400100653001900124653001800143653002000161653001100181653003000192653002300222653002000245653001300265653001200278653002600290653003500316653001600351653002500367653003900392653001700431653002500448653001800473653003200491245005100523856008300574300001100657490000700668520093700675022001401612       1973                            d  c197310aAntibodies, Bacterial10aAntibody Formation10aAntigens, Bacterial10aAutoantibodies10aB-Lymphocytes10aGraft Rejection10aHumans10aHypersensitivity, Delayed10aImmunity, Cellular10aImmunoglobulins10aLepromin10aleprosy10aLymphocyte Activation10aLymphocyte Culture Test, Mixed10aMacrophages10aMycobacterium leprae10aPeripheral Nervous System Diseases10aPhagocytosis10aSkin Transplantation10aT-Lymphocytes10aTransplantation, Autologous00aImmunological problems in leprosy research. 1.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481057/pdf/bullwho00176-0081.pdf  a345-540 v483 a<p>This Memorandum reviews the present status of knowledge of the immunology of leprosy, with particular attention to developments since the publication of a similar review in 1970. The different types of lepromin reaction and their significance in healthy contacts and in patients with tuberculoid and lepromatous leprosy are discussed. The immunological responsiveness of patients with leprosy is also considered, with special attention to in vitro methods for evaluating this response. Part 2 of the Memorandum will cover possible mechanisms of altered immune response in leprosy (including a tentative scheme to explain the possible genesis of the lepromatous lesion); genetic, nutritional, and hormonal factors; the possibility of vaccination; attempts at immunotherapy; and areas in which further research is needed. A detailed protocol for evaluating the effect of transfer factor in leprosy will be included as an annex.</p>  a0042-9686